FDA Issues Complete Response Letter To Alimera Sciences Regarding New Drug Application For ILUVIEN(R)

Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational drug ILUVIEN®. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.

Full Story →